CGRP单克隆抗体预防性治疗偏头痛疗效和安全性的贝叶斯网状Meta分析

刘鑫; 钟小燕; 李梦雅; 徐昌静; 付礼亚; 田冬梅; 黄毅岚

您当前的位置：

首页 >

文章列表页 >

CGRP单克隆抗体预防性治疗偏头痛疗效和安全性的贝叶斯网状Meta分析

更新时间：2022-06-21

- CGRP单克隆抗体预防性治疗偏头痛疗效和安全性的贝叶斯网状Meta分析
- Efficacy and Safety of Calcitonin Gene-related Peptide Monoclonal Antibodies in the Preventive Treatment of Migraine：A Bayesian Network Meta-analysis
- 中国药房 2020年31卷第18期
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  中图分类号：
- 纸质出版日期：2020，
扫描看全文
刘鑫, 钟小燕, 李梦雅, 等. CGRP单克隆抗体预防性治疗偏头痛疗效和安全性的贝叶斯网状Meta分析[J]. 中国药房, 2020,31(18).

LIU Xin, ZHONG Xiaoyan, LI Mengya, et al. Efficacy and Safety of Calcitonin Gene-related Peptide Monoclonal Antibodies in the Preventive Treatment of Migraine：A Bayesian Network Meta-analysis[J]. China Pharmacy, 2020,31(18).
刘鑫, 钟小燕, 李梦雅, 等. CGRP单克隆抗体预防性治疗偏头痛疗效和安全性的贝叶斯网状Meta分析[J]. 中国药房, 2020,31(18). DOI：

LIU Xin, ZHONG Xiaoyan, LI Mengya, et al. Efficacy and Safety of Calcitonin Gene-related Peptide Monoclonal Antibodies in the Preventive Treatment of Migraine：A Bayesian Network Meta-analysis[J]. China Pharmacy, 2020,31(18). DOI：

摘要

目的：系统评价4种降钙素基因相关肽（CGRP）单克隆抗体预防性治疗偏头痛的疗效和安全性，为临床治疗提供循证参考。方法：计算机检索Cochrane图书馆、PubMed、Embase、中国期刊全文数据库、维普网和万方数据等，收集4种CGRP单克隆抗体（试验组）对比安慰剂（对照组）预防性治疗偏头痛的随机对照试验（RCT）。筛选文献并提取资料后，采用Cochrane系统评价员手册5.1.0提供的偏倚风险评估工具对纳入文献质量进行评价，采用GeMTC0.14.3软件和Stata16.0软件进行贝叶斯网状Meta分析。结果：共纳入19项RCT，共计11392例患者，涉及Erenumab70、140mg/月，Fremanezumab675mg/3月、225mg/月，Galcane-zumab120、240、300mg/月，Eptinezumab100、300mg/3月和安慰剂等10种干预措施。Meta分析结果显示，与对照组比较，4种GGRP单克隆抗体均可显著减少患者每月平均偏头痛天数较基线的变化（MMD）（P＜0.05）；各试验组之间，与Galcanezumab300mg/月[MD＝－1.30，95％CI（－2.59，－0.05），P＜0.05]、Eptinezumab100mg/3月[MD＝－1.18，95％CI（－2.26，－0.03），P＜0.05]比较，Fremanezumab225mg/月可显著减少患者MMD；网状Meta排序结果为Fremanezumab225mg/月＞Fremanezumab675mg/3月＞Galcanezumab120mg/月＞Erenumab140mg/月＞Galcanezumab240mg/月＞Eptinezumab300mg/3月＞Erenumab70mg/月＞Eptinezumab100mg/3月＞Galcanezumab300mg/月＞安慰剂。与对照组比较，4种GGRP单克隆抗体均可显著增加每月平均偏头痛天数较基线减少≥50％的患者比例（MMD50）（P＜0.05）；各试验组之间，与Eptinezumab100mg/3月组比较，Fremane-zumab675mg/3月[OR＝1.51，95％CI（1.02，2.31），P＜0.05]、Fremanezumab225mg/月[OR＝1.58，95％CI（1.05，2.44），P＜0.05]组的MMD50均显著升高；网状Meta排序结果为Fremanezumab225mg/月＞Fremanezumab675mg/3月＞Erenumab140mg/月＞Galcanezumab120mg/月＞Eptinezumab300mg/3月＞Galcanezumab240mg/月＞Erenumab70mg/月＞Galcanezumab300mg/月＞Eptinezumab100mg/3月＞安慰剂。安全性方面，Fremanezumab675mg/3月[OR＝1.31，95％CI（1.05，1.64），P＜0.05]、Galcane-zumab240mg/月[OR＝1.39，95％CI（1.09，1.74），P＜0.05]组患者的总不良反应发生率（AE）均显著高于对照组；各试验组之间，与Galcanezumab240mg/月组比较，Erenumab70mg/月[OR＝0.67，95％CI（0.50，0.93），P＜0.05]、140mg/月[OR＝0.70，95％CI（0.51，0.98），P＜0.05]组患者的AE均显著降低；与Fremanezumab675mg/3月组比较，Erenumab70mg/月[OR＝0.72，95％CI（0.52，0.98），P＜0.05]组患者的AE显著降低；网状Meta排序结果为Galcanezumab240mg/月＞Fremanezumab675mg/3月＞Galcane-zumab120mg/月＞Galcanezumab300mg/月＞Eptinezumab300mg/3月＞Fremanezumab225mg/月＞Eptinezumab100mg/3月＞安慰剂＞Erenumab140mg/月＞Erenumab70mg/月。结论：4种CGRP单克隆抗体均能预防性治疗偏头痛，其中Fremanezumab225mg/月的疗效可能最佳，Erenumab70mg/月的安全性可能最高。

Abstract

OBJECTIVE：To systematically evaluate th e efficacy and safety of 4 kinds of calcitonin gene-related peptide （CGRP）monoclonal antibodies in the preventive treatment of migraine ，and to provide evidence-based reference for the clinical treatment of migraine. METHODS ：Retrieved from the Cochrane Library ，PubMed，Embase，CJFD，VIP and Wanfang database ， RCTs about 4 kinds of CGRP monoclonal antibodies （trial Δ 基金项目：四川省科技厅重点研发（重大科技专项）项目 group） versus placebo （control group ） in the preventive （No.2019YFS0180）＊硕士研究生。研究方向：临床药学、循证药学。电话：0830- treatment of migraine were collected. After literature screening 3165787。E-mail：lewxinn@outlook.com and data extraction ， the quality evaluation of included # 通信作者：教授，硕士生导师，硕士。研究方向：临床药学、循证 literature was performed by using the bias risk assessment tool 药学。电话：0830-3165787。E-mail：hyl3160131@163.com provided by the Cochrane system evaluator manual 5.1.0. 中国药房 2020年第31卷第18期 China Pharmacy 2020Vol. 31 No. 18 ·2275· Bayesian network Meta-analysis was performed by using GeMTC 0.14.3 software and Stata 16.0 software. RESULTS ：A total of 19 RCTs involving 11 392 patients were included ，involving 10 interventions，such as Erenumab 70，140 mg/month；Fremanezumab 675 mg/3 months，225 mg/month；Galcanezumab 120，240，300 mg/month；Eptinezumab 100 mg/3 months，300 mg/3 months and placebo. Results of Meta-analysis showed that compared with control group ，4 kinds of CGRP monoclonal antibodies significantly reduced the change of mean monthly migraine days （MMD）（P＜0.05）. Among trial groups ，compared with Galcanezumab 300 mg/month [MD ＝－1.30，95％CI（－2.59，－0.05），P＜0.05] and Eptinezumab 100 mg/3 months [MD ＝－1.18， 95％CI（－2.26，－0.03），P＜0.05]，Fremanezumab 225 mg/month could significantly reduce MMD. Network Meta-analysis ranking showed that Fremanezumab 225 mg/month＞Fremanezumab 675 mg/3 months＞Galcanezumab 120 mg/month＞Erenumab 140 mg/month＞Galcanezumab 240 mg/month＞Eptinezumab 300 mg/3 months＞Erenumab 70 mg/month＞Eptinezumab 100 mg/3 months＞Galcanezumab 300 mg/month＞placebo. Compared with control group ，4 kinds of CGRP monoclonal antibodies were significantly increased of the proportion of patients whose mean monthly migraine days reduction ≥50％ compared with baseline （MMD 50）（P＜0.05）. Among trial groups ，compared with Eptinezumab 100 mg/3 months group ，MMD 50 of Fremanezumab 675 mg/3 months group [OR ＝1.51，95％CI（1.02，2.31），P＜0.05]，Fremanezumab 225 mg/month group [OR ＝1.58，95％CI （1.05，2.44），P＜0.05] were increased significantly. Network Meta-analysis ranking showed that Fremanezumab 225 mg/month＞ Fremanezumab 675 mg/3 months＞Erenumab 140 mg/month＞Galcanezumab 120 mg/month＞Eptinezumab 300 mg/3 months＞ Galcanezumab 240 mg/month＞Erenumab 70 mg/month＞Galcanezumab 300 mg/month＞Eptinezumab 100 mg/3 months＞placebo. In terms of safety ，incidence of total adverse events （AE）of trial groups receiving Fremanezumab 675 mg/3 months [OR ＝1.31， 95％CI（1.05，1.64），P＜0.05]，Galcanezumab 240 mg/month [OR ＝1.39，95％CI（1.09，1.74），P＜0.05] were significantly higher than control group. Among trial groups ，compared with Galcanezumab 240 mg/month group ，AE of Erenumab 70 mg/month group [OR ＝0.67，95％CI（0.50，0.93），P＜0.05]，Erenumab 140 mg/month group [OR ＝0.70，95％CI（0.51，0.98），P＜0.05] were decreased significantly. Compared with Fremanezumab 675 mg/3 months group ，AE of Erenumab 70 mg/month group [OR ＝ 0.72，95％CI（0.52，0.98），P＜0.05] were decreased significantly. Network Meta-analysis ranking showed that Galcanezumab 240 mg/month＞ Fremanezumab 675 mg/3 months＞Galcanezumab 120 mg/month＞Galcanezumab 300 mg/month＞Eptinezumab 300 mg/3 months＞Fremanezumab 225 mg/month＞Eptinezumab 100 mg/3 months＞placebo＞Erenumab 140 mg/month＞Erenumab 70 mg/month. CONCLUSIONS ：Four kinds of CGRP monoclonal antibodies are effective in the preventive treatment of migraine ， among which Fremanezumab 225 mg/month is most likely to have the best efficacy and Erenumab 70 mg/month is most likely to have the highest safety.

关键词

降钙素基因相关肽单克隆抗体预防性治疗偏头痛贝叶斯网状Meta分析疗效安全性

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中成药复方制剂联合常规治疗用于寻常型银屑病疗效与安全性的贝叶斯网状Meta分析

复方苦参注射液联合拉米夫定治疗慢性乙型肝炎肝硬化的疗效观察

盐酸米诺环素软膏联合甲硝唑药膜治疗牙周病的临床观察

乳果糖与白醋稀释液灌肠辅助治疗早期肝昏迷的疗效观察

氯地松乳膏治疗皮炎湿疹类皮肤病的临床疗效评价